Immune checkpoint inhibitors have revolutionized the treatment of multiple oncology indications but the high costs associated with these agents present significant challenges for payers. The potential for label expansions into additional indications and combinatorial approaches involving immune checkpoint inhibitors will put further pressure on MCO commercial plans. Developing a clear understanding of the reimbursement landscape and effect on prescribing is critical for maximizing commercialization of immune checkpoint inhibitors. This content examines the current and future reimbursement dynamics for immune checkpoint inhibitors in the United States with a focus on key indications— malignant melanoma, bladder cancer, and squamous cell carcinoma of the head and neck (SCCHN).
Access & Reimbursement: Provides in-depth insight regarding the impact of payer policy on physician prescribing behavior so you can build your market access strategy and optimize your brand positioning.